#GLP1

Thai consumers face mounting risks from sophisticated international scam networks operating fake online stores that exploit growing demand for weight-loss medications, particularly products claiming to mimic popular diabetes treatments like Ozempic and Mounjaro. Investigative research reveals that more than 140 websites have pivoted from fashion retail facades to targeting vulnerable weight-loss seekers with fraudulent “plant-based oral solutions” that promise pharmaceutical-grade results without medical supervision. These ghost store operations employ stolen professional identities, artificial intelligence-generated testimonials, and elaborate fake endorsements to exploit Thailand’s thriving digital marketplace and cultural emphasis on physical appearance.

Thai consumers are being urged to exercise heightened caution when purchasing weight-loss solutions online, following revelations from Australia about a new wave of “ghost stores” scamming buyers with fake GLP-1 products and predatory advertising—a scam that could easily spread to Thailand’s thriving digital marketplaces. These ghost stores, uncovered by investigative journalists at The Guardian, have been found impersonating real businesses and health experts to sell supposedly plant-based oral supplements that mimic the effects of popular diabetes and weight-loss medications such as Ozempic and Mounjaro, posing direct risks to consumer financial safety and, more alarmingly, their health (theguardian.com).

Scientists have uncovered a potential natural alternative to Ozempic, the popular diabetes and weight-loss medication, by tapping into the power of gut microbes that can regulate blood sugar levels and curb sugar cravings. The latest research, led by a team from Jiangnan University in China and published in Nature Microbiology, points to the gut bacterium Bacteroides vulgatus and its metabolites as key players in stimulating the body’s natural production of glucagon-like peptide-1 (GLP-1), a hormone crucial for maintaining healthy blood sugar and satiety. While initial results are based on animal studies, this discovery raises fresh hope for safer, more accessible strategies to treat diabetes—potentially transforming the landscape for millions of people in Thailand and around the globe who struggle with blood sugar management and sugar cravings [ScienceAlert].

A social media fitness influencer with over five million followers has ignited a widespread controversy after publicly sharing that her recent weight loss success involved the use of a GLP-1 class medication, commonly known by names such as Ozempic and Mounjaro. The disclosure, made in a YouTube video titled “Let’s talk: Therapy, GLP-1 & The Truth About My Recent Weight Loss,” has set off heated discussions about transparency, ethical responsibility, and the realities of the online wellness industry.